Eli Lilly bags an early-stage biotech for the neuro team — paying $135M cash and offering $1B-plus in milestones
Eli Lilly is snapping up a little Cambridge-based biotech to add to their neuro group.
The pharma giant is getting Disarm Therapeutics and its SARM1 inhibitors for axonal degeneration, which has potential to be used for peripheral neuropathy, ALS and MS.
It’s costing Lilly $135 million cash plus up to $1.225 billion in milestones — if it all pays out. In return, they’re getting a biotech that posted preclinical results last fall, with a long haul ahead in the clinic.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 92,100+ biopharma pros reading Endpoints daily — and it's free.